STOCK TITAN

DataMeds AI and Tollo Health Announce Launch of 'Health Lives Here' Mobile Application

Patients can route prescriptions to a local pharmacy of their choice instead of using Corexa’s pharmacy.

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
AI

DataMeds AI (MEDS) and Tollo Health launched the Health Lives Here app, initially focused on people using GLP-1 medications.

The app offers telehealth consultations, access to cash-pay branded GLP-1 medicines through DataMeds subsidiary Corexa Health’s pharmacy, Tollo Health nutrition products, wearable-data tracking and an AI health coach. NFL Alumni Health is helping market it. A national network is being established from Corexa’s 6,500+ independent-pharmacy network; Moose Pharmacy of Concord is the first participating store.

The companies intend to add patients with Long COVID in fourth-quarter 2026, followed by cancer patients. Direct-to-consumer lab tests are planned soon where permitted by law. DataMeds plans a digital-twin option—a virtual patient model—and a provider network for 2027.

Loading...
Loading translation...

Positive

  • Health Lives Here app launched with an initial focus on users of GLP-1 medications.

Negative

  • None.

Market Context

The Sep 25 summit notice referenced this app before launch and shares moved 0.73% pre-publication; t...
Analysis

The Sep 25 summit notice referenced this app before launch and shares moved 0.73% pre-publication; this release advanced the same program from a planned discussion to a launched service.

Key Figures

Planned patient-population expansion: Q4 2026 Independent pharmacy network: 6,500+ independent pharmacies
Planned patient-population expansion
Q4 2026
Planned expansion to include patients with Long COVID
Independent pharmacy network
6,500+ independent pharmacies
Corexa network from which the Health Lives Here pharmacy network is being established

Previous AI Reports

1 past event · Latest: Sep 25
Same Type 1 event
  1. Sep 25

    App presentation

    24h Move
    +0.7%

    Announced a summit presentation discussing the Health Lives Here app and NFL Alumni Health campaign.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

glp-1 receptor agonist, direct-to-consumer lab tests, digital twin, blockchain
4 terms
glp-1 receptor agonist medical
"initially focused on supporting users of GLP-1 receptor agonist medications"
A GLP-1 receptor agonist is a medicine that mimics a natural gut hormone to trigger insulin release, slow stomach emptying, and curb appetite — like using a key to turn on a lock that controls blood sugar and hunger signals. For investors, these drugs matter because they treat common conditions such as diabetes and obesity, can drive large prescription and sales growth, reshape healthcare costs, and heavily affect drug pipelines, competition and company valuations.
direct-to-consumer lab tests medical
"offer direct-to-consumer lab tests (available where permitted by law)"
Laboratory tests sold and delivered directly to consumers without requiring a visit to a doctor or clinic; customers order kits or services online or in stores, provide a specimen (like saliva or a finger-prick blood sample), and receive results directly from the testing company or a portal. Important to investors because business models, revenue growth, regulatory oversight, and lab partnerships affect profitability and risk much like a retailer’s sales channel and quality controls determine its success.
digital twin technical
"A digital twin in healthcare is a virtual replica of a patient"
A digital twin is a live virtual replica of a physical asset, process, or system that mirrors real-world behavior using data and models so users can test changes, predict problems, and measure performance without touching the real thing. For investors, digital twins matter because they can lower maintenance costs, speed product development, improve uptime and reliability, and make future cash flows and risks easier to forecast — like using a flight simulator to safely train and tune a real airplane.
blockchain technical
"put all this healthcare data on a proprietary blockchain"
A blockchain is a digital record-keeping system that securely stores information across many computers, making it difficult to alter or tamper with. Think of it like a shared, unchangeable ledger that everyone can see and verify, ensuring transparency and trust. For investors, this technology offers a way to securely track transactions and assets without relying on a central authority, potentially reducing costs and increasing security.
View in glossary

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

TAMPA, FL / ACCESS Newswire / September 28, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its artificial intelligence platform EinsteinRx™ and smart contracts platform PharmacyChain™, and Tollo Health, LLC ("Tollo"), a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, today announced the launch of the Health Lives Here mobile application, initially focused on supporting users of GLP-1 receptor agonist medications. The companies intend to expand the target patient populations in the fourth quarter of 2026 to include patients with Long COVID, and thereafter cancer patients. Marketing of the application is being driven through the companies' partnership with NFL Alumni Health, the health-focused division of the National Football League Alumni Association.

The launch of the Health Lives Here mobile application coincides with the creation of a national 'Health Lives Here' healthcare network, beginning with key independent pharmacies that provide value-added patient services selected from among DataMEDS' wholly-owned pharmacy-focused subsidiary Corexa Health's ("Corexa") independent pharmacy network. The first Health Lives Here pharmacy is Moose Pharmacy of Concord in Concord, NC.

"What patients really want is for healthcare to be as easy to use as the apps they rely on every day," said Gerald Commissiong, Interim Co-CEO of DataMEDS. "Health Lives Here gives patients one front door to telehealth, their local pharmacist and their own health data, and with NFL Alumni Health, we have messengers who can meet people where they are, including in rural and underserved communities."

"We are excited to help DataMEDS and Tollo Health launch Health Lives Here, especially to help improve healthcare access for patients in rural communities," said Brad Edwards, CEO of the NFL Alumni Association.

https://www.nflalumni.org/

Download the 'Health Lives Here' mobile app for Apple Devices[1] and Android devices[2].

Key features of the Health Lives Here app and campaign:

  1. Telemedicine Services: In-app access to asynchronous and synchronous consultations with licensed physicians who can evaluate patients for, prescribe and help manage GLP-1 therapies, where clinically appropriate.
  2. Pharmacy Services: Corexa's pharmacy offers cash-pay options to purchase FDA-approved branded GLP-1 receptor agonist medications within the app, whether through a new telehealth prescription or a transfer from another pharmacy, with direct delivery directly to patients' homes. In the event Corexa's pharmacy is not a patient's preferred option, the patient is able to route their prescription(s) to a local pharmacy of their choosing.
  3. Targeted Nutritional Support: Users will be able to purchase products marketed by Corexa's pharmacy directly in the app, including Tollo Health's proprietary medical food Forzet™ that is indicated for the dietary management of muscle loss associated with weight loss therapies, available without a prescription. Corexa's pharmacy also markets Tollo Health's antiviral products Galectovid™, indicated for the dietary management of Galectin 1 & 3 associated viral infections, and 3CL protease inhibitor cleansing dietary supplement Tollovid®, both also available without a prescription.
  4. Health Lives Here Pharmacies: A national network of independent pharmacies is being established from among Corexa's 6,500+ independent pharmacy network to make products available at local retail locations, as well as provide value-added services, including pharmacy consultations, to help patients better manage their prescription and OTC product consumption to optimize their treatment regimens.
  5. Wearables Data Tracking: The app integrates health data from popular wearables, including Apple Watch®, Samsung Galaxy Watch®, WHOOP® and Oura Ring®, so users can view activity, sleep and other metrics in one place. As understanding of the utility of this data grows, the Company anticipates being able to provide more personalized insights based on users' health profiles.
  6. Behavioral Health: The app was built around behavioral health and personalized habit-building. The app features an AI health coach, activity logs and an AI chatbot. The AI chatbot is designed to recognize crisis language and direct users to the 988 Suicide & Crisis Lifeline and emergency resources. Additionally, the app logs sleep, movement and mood so users can see trends over time.
  7. Diagnostic Lab Services: Through the acquisition of Helomics Corporation (Helomics) by DataMEDS, the app will soon be able to offer direct-to-consumer lab tests (available where permitted by law) that a patient will be able to order for 'in-home' or 'at the pharmacy' sample collection. Test results will be made available in the app and will be able to be tracked over time if the user chooses to do repeat testing. Physicians will also be able to prescribe tests that will be run at Helomics, whether for general health, Long COVID or cancer. Helomics is preparing to expand its test menu to support these activities and has a pre-existing reference lab agreement with one of the large national diagnostic testing companies, allowing Helomics to offer a broad test menu while remaining the point of contact for patients' results that will help maintain patient engagement.
  8. Patient Electronic Health Records and Digital Twin Development (coming in 2027): A digital twin in healthcare is a virtual replica of a patient that utilizes real-time data to create a dynamic model that can simulate various scenarios, helping healthcare professionals to make better decisions and optimize treatment plans over time. The Company intends to make available the digital twin option for users to build their entire healthcare profile within the app, including medical records, test results, wearables data, dietary supplement use, nutritional data and mental health history. Ultimately, the Company intends to make available the option for users to put all this healthcare data on a proprietary blockchain, giving users control over who can access their health data, with the option to opt in to share de-identified data and participate in any value it generates.
  9. Provider Network (coming in 2027): The Company also plans to build a Health Lives Here provider network to integrate with the ecosystem so that patients can have a fully integrated healthcare experience.

The companies believe the Health Lives Here ecosystem will be especially valuable to underserved and rural communities by increasing awareness of healthy living, improving access to affordable pharmacy services and unique products, and giving patients more control over their health data.

For more information, visit the Company's website at www.datamedsai.com, Tollo Health's website at www.tollohealth.com and Health Lives Here websites at www.healthliveshere.ai (patient access initiative) and www.healthliveshereapp.com (mobile application).

Gerald Commissiong is the Interim Co-CEO of DataMEDS and the CEO of Tollo Health. HealthBridge Advisors is the controlling shareholder of Tollo Health, LLC. Tollo Health contracted with NuPath AI for the development of the Health Lives Here mobile application.

Trademarks used in this press release belong to their respective owners.

About DataMeds AI, Inc.

DataMeds AI, Inc. (NASDAQ:MEDS) (formerly Wellgistics Health, Inc.) is a healthcare company that focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent and telemedicine business units through its Health IT platforms to deliver a better experience for consumers and providers. Headquartered in Tampa, Fla., DataMEDS incorporates the artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contracts platform PharmacyChain™ into Tollo Health, LLC's Health Lives Here mobile application, and its Corexa Health subsidiary provides pharmacy dispensing and pharmacy-related services, including the distribution of products developed by Tollo Health.

About Tollo Health

Tollo Health, LLC is a healthcare company commercializing proprietary medical foods and dietary supplements and, through TolloBio, developing biopharmaceutical candidates, alongside its Health Lives Here mobile application. Corexa Health, a subsidiary of DataMeds AI, Inc., distributes select Tollo Health medical foods and dietary supplements under a wholesale distribution arrangement.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are not predictions of actual performance. Forward-looking statements include, without limitation, statements regarding: future events, including, but not limited to, the companies' intent to expand the target patient populations of Health Lives Here to include patients with Long COVID in the fourth quarter of 2026, the companies' intent to expand to include cancer patients, the continued availability of the Health Lives Here mobile application, the implementation and expansion of Helomics' lab services, the development of digital twin capabilities, the development of a proprietary blockchain and the development of provider-network features, the creation of the Health Lives Here pharmacy network, the success of the NFL Alumni Health partnership, the companies' proposed transaction with DataVault AI Inc. (NASDAQ: DVLT), Scilex Holding Company, EOS Holdings and HealthBridge Advisors (controlling shareholder of Tollo Health, LLC); the satisfaction or waiver of closing conditions applicable to any of the foregoing; the receipt of stockholder approval and any other required approvals; the Company's anticipated business strategy, operating plans and growth opportunities; the integration of telemedicine, pharmacy, laboratory, wearable-device, artificial intelligence, blockchain and data-management technologies; the proposed development, commercialization and expansion of EinsteinRx AI, PharmacyChain, Health Lives Here and related platforms; the anticipated growth of the market for Long COVID products and related treatment approaches; the companies' ability to empower patients to access, manage, control or monetize health data; the anticipated benefits of the companies' technology platforms, strategic relationships and business combinations; the Company's capitalization, outstanding securities, lock-up arrangements, public float and registration statements; the Company's ability to maintain compliance with Nasdaq listing standards; and the Company's liquidity, capital resources and ability to fund operations. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a number of risks and uncertainties, including those described under "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent filings with the Securities and Exchange Commission. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

DataMeds AI Media Contact
James Lambert, Vice President
Rubenstein Public Relations
Phone: 212.805.3024
Email: jlambert@rubensteinpr.com

DataMeds AI Investor Contact
Investor Relations: IR@datamedsai.com

###


SOURCE: DataMEDS AI, Inc.



View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the DataMeds AI and Tollo Health Health Lives Here app offer?

The app brings together telehealth consultations, pharmacy access, products marketed by Corexa’s pharmacy, wearable-data tracking and behavioral-health tools. Its initial focus is people using GLP-1 medications; licensed physicians can evaluate patients for treatment and prescribe it where clinically appropriate.

When will Health Lives Here expand beyond GLP-1 medication users?

DataMeds AI and Tollo Health intend to add patients with Long COVID in fourth-quarter 2026, followed by cancer patients. Those expansions are plans, not features described as available at launch.

Can Health Lives Here users choose a pharmacy other than Corexa’s?

Yes. Users can route prescriptions to a local pharmacy of their choosing if Corexa’s pharmacy is not their preferred option. Corexa’s pharmacy also offers cash-pay purchases of FDA-approved branded GLP-1 medicines through a new telehealth prescription or a transferred prescription.

How are lab tests expected to work in the Health Lives Here app?

Planned direct-to-consumer tests would allow in-home or at-the-pharmacy sample collection where permitted by law, with results available in the app. Physicians would also be able to prescribe tests run at Helomics. Helomics is preparing to expand its test menu.

What health-data controls does DataMeds AI plan for Health Lives Here?

DataMeds plans an option for users to place their health data on a proprietary blockchain and control who can access it. Users would also have the option to share de-identified data and participate in any value it generates. These are planned features, not current app capabilities.

Keep reading